Moreover, refinement of the palindromic structure to generate combined selective TLR7/TLR9 inhibitors [37] together with anti-B-cell-depleting protocols [23] to re-establish critical B-cell differentiation checkpoints [69] may result in better treatments for human lupus. This evidence concerns the gene TLR7 and systemic lupus erythematosus.